Recommendations for treatment of critically ill patients with COVID-19 : Version 3 S1 guideline
© 2020. Springer Medizin Verlag GmbH, ein Teil von Springer Nature..
Since December 2019 a novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) has rapidly spread around the world resulting in an acute respiratory illness pandemic. The immense challenges for clinicians and hospitals as well as the strain on many healthcare systems has been unprecedented.The majority of patients present with mild symptoms of coronavirus disease 2019 (COVID-19); however, 5-8% become critically ill and require intensive care treatment. Acute hypoxemic respiratory failure with severe dyspnea and an increased respiratory rate (>30/min) usually leads to intensive care unit (ICU) admission. At this point bilateral pulmonary infiltrates are typically seen. Patients often develop a severe acute respiratory distress syndrome (ARDS).So far, remdesivir and dexamethasone have shown clinical effectiveness in severe COVID-19 in hospitalized patients. The main goal of supportive treatment is to ascertain adequate oxygenation. Invasive mechanical ventilation and repeated prone positioning are key elements in treating severely hypoxemic COVID-19 patients.Strict adherence to basic infection control measures (including hand hygiene) and correct use of personal protection equipment (PPE) are essential in the care of patients. Procedures that lead to formation of aerosols should be carried out with utmost precaution and preparation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
|---|---|
| Enthalten in: |
Der Anaesthesist - 70(2021), Suppl 1 vom: 05. Dez., Seite 19-29 |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
Empfehlungen für die Behandlung von kritisch kranken Patienten mit COVID-19 : Version 3 S1-Leitlinie |
|---|
| Beteiligte Personen: |
Kluge, S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 20.12.2021 Date Revised 17.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00101-020-00879-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318118610 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318118610 | ||
| 003 | DE-627 | ||
| 005 | 20231225164703.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00101-020-00879-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1060.xml |
| 035 | |a (DE-627)NLM318118610 | ||
| 035 | |a (NLM)33245382 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kluge, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recommendations for treatment of critically ill patients with COVID-19 |b Version 3 S1 guideline |
| 246 | 3 | 3 | |a Empfehlungen für die Behandlung von kritisch kranken Patienten mit COVID-19 : Version 3 S1-Leitlinie |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.12.2021 | ||
| 500 | |a Date Revised 17.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020. Springer Medizin Verlag GmbH, ein Teil von Springer Nature. | ||
| 520 | |a Since December 2019 a novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) has rapidly spread around the world resulting in an acute respiratory illness pandemic. The immense challenges for clinicians and hospitals as well as the strain on many healthcare systems has been unprecedented.The majority of patients present with mild symptoms of coronavirus disease 2019 (COVID-19); however, 5-8% become critically ill and require intensive care treatment. Acute hypoxemic respiratory failure with severe dyspnea and an increased respiratory rate (>30/min) usually leads to intensive care unit (ICU) admission. At this point bilateral pulmonary infiltrates are typically seen. Patients often develop a severe acute respiratory distress syndrome (ARDS).So far, remdesivir and dexamethasone have shown clinical effectiveness in severe COVID-19 in hospitalized patients. The main goal of supportive treatment is to ascertain adequate oxygenation. Invasive mechanical ventilation and repeated prone positioning are key elements in treating severely hypoxemic COVID-19 patients.Strict adherence to basic infection control measures (including hand hygiene) and correct use of personal protection equipment (PPE) are essential in the care of patients. Procedures that lead to formation of aerosols should be carried out with utmost precaution and preparation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Janssens, U |e verfasserin |4 aut | |
| 700 | 1 | |a Welte, T |e verfasserin |4 aut | |
| 700 | 1 | |a Weber-Carstens, S |e verfasserin |4 aut | |
| 700 | 1 | |a Schälte, G |e verfasserin |4 aut | |
| 700 | 1 | |a Salzberger, B |e verfasserin |4 aut | |
| 700 | 1 | |a Gastmeier, P |e verfasserin |4 aut | |
| 700 | 1 | |a Langer, F |e verfasserin |4 aut | |
| 700 | 1 | |a Welper, M |e verfasserin |4 aut | |
| 700 | 1 | |a Westhoff, M |e verfasserin |4 aut | |
| 700 | 1 | |a Pfeifer, M |e verfasserin |4 aut | |
| 700 | 1 | |a Hoffmann, F |e verfasserin |4 aut | |
| 700 | 1 | |a Böttiger, B W |e verfasserin |4 aut | |
| 700 | 1 | |a Marx, G |e verfasserin |4 aut | |
| 700 | 1 | |a Karagiannidis, C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Der Anaesthesist |d 1952 |g 70(2021), Suppl 1 vom: 05. Dez., Seite 19-29 |w (DE-627)NLM00001253X |x 1432-055X |7 nnns |
| 773 | 1 | 8 | |g volume:70 |g year:2021 |g number:Suppl 1 |g day:05 |g month:12 |g pages:19-29 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00101-020-00879-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 70 |j 2021 |e Suppl 1 |b 05 |c 12 |h 19-29 | ||